METHADONE INITIATION IN THE EMERGENCY DEPARTMENT FOR OPIOID USE DISORDER: A CASE SERIES

[1]  M. Greenwald,et al.  A Neuropharmacological Model to Explain Buprenorphine Induction Challenges. , 2022, Annals of emergency medicine.

[2]  S. Nahvi,et al.  Adapting methadone inductions to the fentanyl era. , 2022, Journal of substance abuse treatment.

[3]  M. Saheed,et al.  Models for Implementing Emergency Department-Initiated Buprenorphine with Referral for Ongoing Medication Treatment at Emergency Department Discharge in Diverse Academic Centers. , 2022, Annals of emergency medicine.

[4]  V. Ganetsky,et al.  Attitudes on Methadone Utilization in the Emergency Department: A Physician Cross-sectional Study , 2022, The western journal of emergency medicine.

[5]  S. Springer,et al.  Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community , 2022, Addiction Science & Clinical Practice.

[6]  S. Shoptaw,et al.  Rapid Adoption of Low-Threshold Buprenorphine Treatment at California Emergency Departments Participating in the CA Bridge Program. , 2021, Annals of emergency medicine.

[7]  Lewis S. Nelson,et al.  Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department. , 2021, Annals of emergency medicine.

[8]  L. Degenhardt,et al.  Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. , 2021, JAMA psychiatry.

[9]  G. D’Onofrio,et al.  Emergency Department Visits for Nonfatal Opioid Overdose During the COVID-19 Pandemic Across Six US Health Care Systems , 2021, Annals of Emergency Medicine.

[10]  Saeed Ahmed,et al.  Microinduction of Buprenorphine/Naloxone: A Review of the Literature. , 2020, The American journal on addictions.

[11]  K. Peterson,et al.  Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review , 2020, Journal of General Internal Medicine.

[12]  S. Springer,et al.  A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder. , 2020, Journal of substance abuse treatment.

[13]  J. Rich,et al.  One year of methadone maintenance treatment in a fentanyl endemic area: Safety, repeated exposure, retention, and remission. , 2020, Journal of substance abuse treatment.

[14]  J. J. Lynch,et al.  Management of Opioid Use Disorder in the Emergency Department: A White Paper Prepared for the American Academy of Emergency Medicine. , 2020, The Journal of emergency medicine.

[15]  E. Stuart,et al.  Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. , 2020, Addiction.

[16]  S. Martins,et al.  "Everything is not right anymore": Buprenorphine experiences in an era of illicit fentanyl. , 2019, The International journal on drug policy.

[17]  R. Hoffman,et al.  Low dose intramuscular methadone for acute mild to moderate opioid withdrawal syndrome , 2018, The American journal of emergency medicine.

[18]  H. Duber,et al.  Identification, Management, and Transition of Care for Patients With Opioid Use Disorder in the Emergency Department , 2018, Annals of emergency medicine.

[19]  M. Kahan,et al.  Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone? , 2017, Canadian family physician Medecin de famille canadien.

[20]  G. D’Onofrio,et al.  Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention , 2017, Journal of General Internal Medicine.

[21]  C. Green,et al.  Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis. , 2016, Drug and alcohol dependence.

[22]  C. Timko,et al.  Retention in medication-assisted treatment for opiate dependence: A systematic review , 2016, Journal of addictive diseases.

[23]  G. D’Onofrio,et al.  Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. , 2015, JAMA.

[24]  Julio S. G. Montaner,et al.  The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. , 2014, Addiction.

[25]  J. Hahn,et al.  Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. , 2014, JAMA internal medicine.

[26]  W. Ling,et al.  HIV Risk Reduction With Buprenorphine–Naloxone or Methadone: Findings From a Randomized Trial , 2014, Journal of acquired immune deficiency syndromes.

[27]  C. Cunningham,et al.  Factors associated with complicated buprenorphine inductions. , 2010, Journal of substance abuse treatment.

[28]  R. D. Bruce.  Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings. , 2010, The International journal on drug policy.

[29]  J. Bell,et al.  Comparing overdose mortality associated with methadone and buprenorphine treatment. , 2009, Drug and alcohol dependence.

[30]  J. Strang,et al.  Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. , 2009, Journal of substance abuse treatment.

[31]  R P Mattick,et al.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. , 2008, The Cochrane database of systematic reviews.